Protalix Biotherapeutics Stock Debt To Equity

PLX Stock

USD 1.83 0.07 3.98%

Protalix Biotherapeutics fundamentals help investors to digest information that contributes to Protalix Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Protalix Stock. The fundamental analysis module provides a way to measure Protalix Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Protalix Biotherapeutics stock.

		Last Reported	Projected for Next Year
	Debt To Equity	0.65	0.68

Debt To Equity is likely to rise to 0.68 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Protalix Biotherapeutics Company Debt To Equity Analysis

Protalix Biotherapeutics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Current Protalix Biotherapeutics Debt To Equity

0.68

Most of Protalix Biotherapeutics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Protalix Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Protalix Debt To Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Protalix Biotherapeutics is extremely important. It helps to project a fair market value of Protalix Stock properly, considering its historical fundamentals such as Debt To Equity. Since Protalix Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Protalix Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Protalix Biotherapeutics' interrelated accounts and indicators.

	Total Assets	Net Debt	Net Receivables	Total Liab	Total Current Assets	Total Stockholder Equity	Retained Earnings	Short Term Debt	Common Stock	Accounts Payable	Short Term Investments	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt	Capital Surpluse	Short Long Term Debt	Long Term Debt Total	Net Invested Capital	Cash And Equivalents	Net Working Capital	Capital Stock
Total Assets		-0.24	-0.03	0.62	0.99	0.04	-0.22	0.49	0.56	0.09	0.02	0.49	-0.08	0.3	0.52	0.08	0.17	0.02	0.16	0.2	0.2	0.22
Net Debt	-0.24		0.13	0.14	-0.19	-0.35	-0.45	0.16	-0.31	-0.1	0.15	-0.61	0.08	-0.47	0.17	0.41	-0.4	-0.43	-0.2	-0.61	-0.75	-0.58
Net Receivables	-0.03	0.13		0.07	-0.12	-0.11	-0.62	-0.27	-0.02	0.54	0.22	0.14	0.13	-0.21	0.06	0.54	-0.57	-0.19	-0.1	-0.59	-0.29	-0.45
Total Liab	0.62	0.14	0.07		0.59	-0.72	-0.24	0.32	0.49	0.31	-0.29	0.31	0.34	-0.49	0.65	-0.14	-0.05	0.25	-0.46	0.18	-0.07	0.14
Total Current Assets	0.99	-0.19	-0.12	0.59		0.07	-0.19	0.49	0.57	-0.03	0.03	0.37	-0.1	0.32	0.57	0.09	0.16	0.03	0.17	0.22	0.22	0.25
Total Stockholder Equity	0.04	-0.35	-0.11	-0.72	0.07		0.03	0.04	-0.13	-0.33	0.45	0.0	-0.52	0.85	-0.32	0.24	0.18	-0.34	0.82	-0.12	0.24	-0.07
Retained Earnings	-0.22	-0.45	-0.62	-0.24	-0.19	0.03		-0.03	-0.04	-0.3	-0.57	0.07	-0.26	0.08	-0.17	-0.86	0.72	0.6	-0.13	0.76	0.55	0.72
Short Term Debt	0.49	0.16	-0.27	0.32	0.49	0.04	-0.03		0.07	0.04	0.07	0.25	-0.29	0.09	-0.03	-0.04	0.35	-0.31	0.28	-0.03	-0.24	-0.02
Common Stock	0.56	-0.31	-0.02	0.49	0.57	-0.13	-0.04	0.07		0.16	-0.36	0.28	0.17	0.06	0.38	-0.17	-0.08	0.43	-0.06	0.47	0.51	0.64
Accounts Payable	0.09	-0.1	0.54	0.31	-0.03	-0.33	-0.3	0.04	0.16		0.08	0.61	0.35	-0.13	-0.2	0.08	-0.15	-0.12	-0.14	-0.06	-0.2	-0.14
Short Term Investments	0.02	0.15	0.22	-0.29	0.03	0.45	-0.57	0.07	-0.36	0.08		-0.07	-0.22	0.34	-0.25	0.68	-0.27	-0.76	0.53	-0.48	-0.33	-0.65
Property Plant Equipment	0.49	-0.61	0.14	0.31	0.37	0.0	0.07	0.25	0.28	0.61	-0.07		-0.11	0.27	-0.15	-0.25	0.48	0.03	0.16	0.3	0.21	0.25
Current Deferred Revenue	-0.08	0.08	0.13	0.34	-0.1	-0.52	-0.26	-0.29	0.17	0.35	-0.22	-0.11		-0.43	0.19	0.14	-0.58	0.19	-0.45	-0.02	-0.09	-0.06
Net Tangible Assets	0.3	-0.47	-0.21	-0.49	0.32	0.85	0.08	0.09	0.06	-0.13	0.34	0.27	-0.43		-0.26	0.13	0.31	-0.26	0.61	0.12	0.29	0.08
Long Term Debt	0.52	0.17	0.06	0.65	0.57	-0.32	-0.17	-0.03	0.38	-0.2	-0.25	-0.15	0.19	-0.26		-0.04	-0.16	0.38	-0.28	0.14	0.21	0.15
Capital Surpluse	0.08	0.41	0.54	-0.14	0.09	0.24	-0.86	-0.04	-0.17	0.08	0.68	-0.25	0.14	0.13	-0.04		-0.69	-0.7	0.27	-0.8	-0.51	-0.72
Short Long Term Debt	0.17	-0.4	-0.57	-0.05	0.16	0.18	0.72	0.35	-0.08	-0.15	-0.27	0.48	-0.58	0.31	-0.16	-0.69		0.14	0.23	0.56	0.3	0.49
Long Term Debt Total	0.02	-0.43	-0.19	0.25	0.03	-0.34	0.6	-0.31	0.43	-0.12	-0.76	0.03	0.19	-0.26	0.38	-0.7	0.14		-0.53	0.72	0.71	0.73
Net Invested Capital	0.16	-0.2	-0.1	-0.46	0.17	0.82	-0.13	0.28	-0.06	-0.14	0.53	0.16	-0.45	0.61	-0.28	0.27	0.23	-0.53		-0.17	0.1	-0.12
Cash And Equivalents	0.2	-0.61	-0.59	0.18	0.22	-0.12	0.76	-0.03	0.47	-0.06	-0.48	0.3	-0.02	0.12	0.14	-0.8	0.56	0.72	-0.17		0.8	0.89
Net Working Capital	0.2	-0.75	-0.29	-0.07	0.22	0.24	0.55	-0.24	0.51	-0.2	-0.33	0.21	-0.09	0.29	0.21	-0.51	0.3	0.71	0.1	0.8		0.8
Capital Stock	0.22	-0.58	-0.45	0.14	0.25	-0.07	0.72	-0.02	0.64	-0.14	-0.65	0.25	-0.06	0.08	0.15	-0.72	0.49	0.73	-0.12	0.89	0.8

Click cells to compare fundamentals

High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.

Competition

Predict Protalix Biotherapeutics

Debt To Equity Over Time

Protalix Liabilities And Stockholders Equity

Liabilities And Stockholders Equity

51.05 Million

At this time, Protalix Biotherapeutics' Liabilities And Stockholders Equity is fairly stable compared to the past year.

Protalix Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Protalix Biotherapeutics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Protalix Biotherapeutics could also be used in its relative valuation, which is a method of valuing Protalix Biotherapeutics by comparing valuation metrics of similar companies.

Protalix Biotherapeutics is currently under evaluation in debt to equity category among its peers.

Protalix Biotherapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Protalix Biotherapeutics from analyzing Protalix Biotherapeutics' financial statements. These drivers represent accounts that assess Protalix Biotherapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Protalix Biotherapeutics' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	48.7M	105.8M	36.7M	66.4M	120.2M	114.2M
Enterprise Value	91.8M	151.9M	31.2M	82.8M	122.8M	116.7M

Protalix Fundamentals

	Return On Equity	-0.43
	Return On Asset	-0.1
	Profit Margin	(0.39) %
	Operating Margin	(0.18) %
	Current Valuation	107.87 M
	Shares Outstanding	73.63 M
	Shares Owned By Insiders	14.53 %
	Shares Owned By Institutions	5.20 %
	Number Of Shares Shorted	3.1 M
	Price To Earning	(1.23) X
	Price To Book	4.00 X
	Price To Sales	3.54 X
	Revenue	65.49 M
	Gross Profit	28.05 M
	EBITDA	11.65 M
	Net Income	8.31 M
	Cash And Equivalents	17.11 M
	Cash Per Share	0.41 X
	Total Debt	26.28 M
	Current Ratio	1.33 X
	Book Value Per Share	0.46 X
	Cash Flow From Operations	(1.32 M)
	Short Ratio	22.71 X
	Earnings Per Share	(0.15) X
	Price To Earnings To Growth	(0.10) X
	Target Price	14.0
	Number Of Employees	208
	Beta	0.67
	Market Capitalization	134.75 M
	Total Asset	84.43 M
	Retained Earnings	(381.55 M)
	Working Capital	24.4 M
	Current Asset	59.65 M
	Current Liabilities	10.33 M
	Net Asset	84.43 M

About Protalix Biotherapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Protalix Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protalix Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protalix Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Protalix Stock Analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC